1-(2-甲氧基苯基)-4-[(2-苯基-1H-咪唑-5-基)甲基]哌嗪 | 144649-74-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-(2-甲氧基苯基)-4-[(2-苯基-1H-咪唑-5-基)甲基]哌嗪
• 英文名称: 2-phenyl-4-<<4-(2-methoxyphenyl)-1-piperazinyl>methyl>imidazole
• 英文别名: Piperazine, 1-(2-methoxyphenyl)-4-[(2-phenyl-1H-imidazol-4-yl)methyl]-；1-(2-methoxyphenyl)-4-[(2-phenyl-1H-imidazol-5-yl)methyl]piperazine
• CAS: 144649-74-1
• 化学式: C₂₁H₂₄N₄O
• 分子量: 348.448
• InChiKey: DVOGAODGHIXYRO-UHFFFAOYSA-N

物化性质

• 沸点：
  566.8±50.0 °C(Predicted)
• 密度：
  1.193±0.06 g/cm3(Predicted)
• 溶解度：
  15.1 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  44.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  苯甲脒 在 ammonium hydroxide 、 氯化亚砜 、 氯化铵 、 三乙胺 作用下， 以 氯仿 为溶剂， 反应 1.17h， 生成 1-(2-甲氧基苯基)-4-[(2-苯基-1H-咪唑-5-基)甲基]哌嗪
  参考文献：
  名称：

  2-Phenyl-4-(aminomethyl)imidazoles as Potential Antipsychotic Agents. Synthesis and Dopamine D2 Receptor Binding

  摘要：

  A series of 2-phenyl-4-(aminomethyl)imidazoles were designed as conformationally restricted analogs of the dopamine D-2 selective benzamide antipsychotics. The title compounds were synthesized and tested for blockade of[H-3]YM-09151 binding in cloned African green monkey dopamine D-2 receptor preparations. The binding affinity data thus obtained were compared against that of the benzamides and a previously described series of 2-phenyl-5-(aminomethyl)-pyrroles.

  DOI：

  10.1021/jm00012a026

文献信息

• Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
  申请人：Neurogen Corporation, Corporation of the State of Delaware

  公开号：US20030018025A1

  公开（公告）日：2003-01-23

  Disclosed are compounds of the formula: 1 wherein R 1 represents optionally substituted aryl, heteroaryl, arylalkyl, or cycloalkyl groups; X, Z, and Y are optionally substituted nitrogen or carbon atoms; R 3 and R 4 are organic or inorganic substitutents which may togther form ring structutes; m is zero, one or two; and R 5 and R 6 are are organic or inorganic substituents; and the pharmaceutically acceptable addition salts thereof, which compounds are highly selective partial agonists or antagonists at brain dopamine receptor subtypes or prodrugs thereof and are useful in the diagnosis and treatment of affective disorders such as schizophrenia and depression as well as certain movement disorders such as Parkinsonism.

  揭示了以下式的化合物： 其中R1代表可选择地取代的芳基、杂环芳基、芳基烷基或环烷基基团；X、Z和Y为可选择地取代的氮或碳原子；R3和R4为有机或无机取代基，可能共同形成环结构；m为零、一或二；R5和R6为有机或无机取代基； 以及其药学上可接受的盐， 这些化合物是高度选择性的部分激动剂或拮抗剂，作用于脑多巴胺受体亚型或其前药，并可用于诊断和治疗情感障碍，如精神分裂症和抑郁症，以及某些运动障碍，如帕金森病。
• 4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new
  申请人：Neurogen Corporation

  公开号：US05681956A1

  公开（公告）日：1997-10-28

  This invention encompasses compounds of the formulas: ##STR1## where R.sub.1 R.sub.3, R.sub.4, R.sub.6, X, Y, and Z are T are variables; and M is ##STR2## where R.sub.2 is a variable; or R.sub.1 and R.sub.2 together may represent --(CH.sub.2).sub.n.sbsb.1 where .sub.n.sbsb.1 is 1, 2, or 3. These compounds are highly selective partial agonists or antagonists at brain dopamine receptor subtypes or prodrugs thereof and are useful in the diagnosis and treatment of affective disorders such as schizophrenia and depression as well as certain movement disorders such as Parkinsonism. Furthermore compounds of this invention may be useful in treating the extrapyramidal side effects asssociated with the use of conventional neuroleptic agents.

  这项发明涵盖了以下化合物的公式：##STR1## 其中R.sub.1、R.sub.3、R.sub.4、R.sub.6、X、Y和Z是T是变量；M为##STR2## 其中R.sub.2是一个变量；或者R.sub.1和R.sub.2可能代表--(CH.sub.2).sub.n.sbsb.1，其中.sub.n.sbsb.1为1、2或3。这些化合物是高度选择性的部分激动剂或拮抗剂，作用于大脑多巴胺受体亚型或其前体药物，可用于诊断和治疗情感障碍，如精神分裂症和抑郁症，以及某些运动障碍，如帕金森病。此外，本发明的化合物可能有助于治疗与传统神经阻滞剂使用相关的肌张力障碍副作用。
• Certain aminomethyl phenylimidazole derivatives; and 4-aryl substituted
  申请人：Neurogen Corporation

  公开号：US05633376A1

  公开（公告）日：1997-05-27

  This invention encompasses compounds of the formulas: ##STR1## where R.sub.1 R.sub.3, R.sub.4, R.sub.6, X, Y, and Z are T are variables; and M is ##STR2## where R.sub.2 is a variable; or R.sub.1 and R.sub.2 together may represent --(CH.sub.2).sub.n1 where n.sub.1 is 1, 2, or 3. These compounds are highly selective partial agonists or antagonists at brain dopamine receptor subtypes or prodrugs thereof and are useful in the diagnosis and treatment of affective disorders such as schizophrenia and depression as well as certain movement disorders such as Parkinsonism. Furthermore compounds of this invention may be useful in treating the extraparamidyl side effects associated with the use of conventional neuroleptic agents.

  本发明涵盖了以下式子的化合物：##STR1## 其中R.sub.1，R.sub.3，R.sub.4，R.sub.6，X，Y和Z是T变量; M是##STR2## 其中R.sub.2是可变的; 或者R.sub.1和R.sub.2可以代表--(CH.sub.2).sub.n1，其中n.sub.1为1、2或3。这些化合物是高度选择性的部分激动剂或拮抗剂，可作为脑多巴胺受体亚型的诊断和治疗以及某些运动障碍（如帕金森综合症）的药物前体。此外，本发明的化合物可用于治疗与传统神经类药物使用相关的外周副作用。
• Certain aminomethyl phenylimidazole derivatives; a class of dopamine
  申请人：Neurogen Corporation

  公开号：US05159083A1

  公开（公告）日：1992-10-27

  This invention encompasses compounds of the formula: ##STR1## where X, Y, Z, T, R.sub.1, R.sub.3, R.sub.4, and R.sub.5 are variables representing various organic and inorganic substituents; M is ##STR2## R.sub.2 and R.sub.6 represent hydrogen or alkyl substituents; or R.sub.1 and R.sub.2 together may represent --(CH.sub.2).sub.n1 where n.sub.1 is 1, 2, or 3; or NR.sub.4 R.sub.5 represents substituted or unsubstituted-tetrahydroisoquinolinyl; or ##STR3## where n is 1, 2, or 3; W is N or CH; and R.sub.7 represents hydrogen or aryl; or W--R.sub.7 is oxygen or sulfur. These compounds are highly selective partial agonists or antagonists at brain dopamine receptor subtypes or prodrugs thereof and are useful in the diagnosis and treatment of affective disorders such as schizophrenia and depression as well as certain movement disorders such as Parkinsonism. Futhermore compounds of this invention may be useful in treating the extraparamidyl side effects associated with the use of conventional neuroleptic agents.

  该发明涵盖了以下结构的化合物：##STR1## 其中X、Y、Z、T、R.sub.1、R.sub.3、R.sub.4和R.sub.5是代表各种有机和无机取代基的变量；M是##STR2## R.sub.2和R.sub.6代表氢或烷基取代基；或者R.sub.1和R.sub.2一起可以代表--(CH.sub.2).sub.n1，其中n.sub.1为1、2或3；或NR.sub.4 R.sub.5代表取代或未取代的四氢异喹啉基；或##STR3## 其中n为1、2或3；W为N或CH；R.sub.7代表氢或芳基；或W--R.sub.7为氧或硫。这些化合物在大脑多巴胺受体亚型上高度选择性地作为部分激动剂或拮抗剂或其前药，可用于诊断和治疗情感障碍，如精神分裂症和抑郁症，以及某些运动障碍，如帕金森病。此外，本发明化合物可能有用于治疗与传统神经精神药物使用相关的外围副作用。
• Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases
  申请人：Yeadon Michael

  公开号：US20070117788A1

  公开（公告）日：2007-05-24

  The present invention relates to a combination of therapeutic agents useful in the treatment of obstructive airways and other inflammatory diseases comprising (I) a dopamine D2-receptor agonist that is therapeutically effective in the treatment of said diseases when administered by inhalation; together with (II) an anti-cholinergic agent consisting of a member selected from the group consisting of tiotropium and derivatives thereof that is therapeutically effective in the treatment of said diseases when administered by inhalation; as well as to a method of treating said obstructive airways and other inflammatory diseases comprising administering to said mammal by inhalation a therapeutically effective amount of said combination of therapeutic agents; and a pharmaceutical composition comprising a pharmaceutically acceptable carrier together with said combination of therapeutic agents; and a package containing a pharmaceutical composition for insertion into a device capable of simultaneous or sequential delivery of said pharmaceutical composition in the form of an aerosol or dry powder dispersion to said mammal, where said device is a metered dose inhaler or a dry powder inhaler. It is preferred that said dopamine D2-receptor agonist component be bromocriptine mesylate, naxagolide hydrochloride, cabergoline, pergolide mesylate, quinpirole hydrochloride, or ropinirole hydrochloride; and that said anti-cholinergic agent component be tiotropium bromide.